tiprankstipranks
Trending News
More News >
Krishna Institute of Medical Sciences Limited (IN:KIMS)
:KIMS
India Market
Advertisement

Krishna Institute of Medical Sciences Limited (KIMS) AI Stock Analysis

Compare
2 Followers

Top Page

IN:KIMS

Krishna Institute of Medical Sciences Limited

(KIMS)

Select Model
Select Model
Select Model
Neutral 65 (OpenAI - 4o)
Rating:65Neutral
Price Target:
₹766.00
▲(4.32% Upside)
Krishna Institute of Medical Sciences Limited demonstrates strong financial performance with significant revenue and profit growth. However, the stock's high valuation and bearish technical indicators suggest caution. The company's increased leverage and negative free cash flow are potential risks that need monitoring.

Krishna Institute of Medical Sciences Limited (KIMS) vs. iShares MSCI India ETF (INDA)

Krishna Institute of Medical Sciences Limited Business Overview & Revenue Model

Company DescriptionKrishna Institute of Medical Sciences Limited provides medical and health care services under the KIMS Hospitals brand name in India. The company offers range of specialties, including cardiac, dental, neuro, oncological, orthopedic, renal, reproductive, and robotic sciences, as well as gastroenterology and hepatology, heart and lung transplant, organ transplantation, mother and childcare, and pediatrics services. It also focuses on accident, biochemistry, anesthesiology, bariatric surgery, andrology and infertility, arthroscopy, alzheimers, bone, joint center specialties, and others. The company was incorporated in 1973 and is based in Secunderabad, India.
How the Company Makes MoneyKIMS generates revenue primarily through patient care services, including inpatient and outpatient treatments, surgeries, and diagnostic services. The company earns money by charging patients for hospital stays, medical procedures, consultations, and specialized treatments. Additional revenue streams include partnerships with insurance companies for cashless treatment options, government health schemes, and corporate tie-ups for employee health programs. KIMS may also benefit from ancillary services such as pharmacy sales, laboratory services, and health check-up packages, which contribute to its overall earnings.

Krishna Institute of Medical Sciences Limited Financial Statement Overview

Summary
Krishna Institute of Medical Sciences Limited shows strong financial health with robust revenue and profit growth, supported by stable margins. Despite increased leverage, the company maintains a solid equity base and strong operational cash generation, although high capital expenditures have led to negative free cash flow.
Income Statement
85
Very Positive
Krishna Institute of Medical Sciences Limited has demonstrated a robust revenue growth trajectory, increasing from 16.5 billion in 2022 to 30.4 billion in 2025, indicating strong market demand and operational efficiency. The gross profit margin remained stable around 62-63%, showcasing effective cost management. Notably, the net profit margin improved to 12.7% in 2025 from 12.4% in 2024, suggesting enhanced profitability. The EBIT margin also showed a strong increase to 62.9% in 2025, reflecting operational excellence. Overall, the company exhibits impressive growth and profitability.
Balance Sheet
78
Positive
The balance sheet of Krishna Institute of Medical Sciences Limited reflects a solid equity base with stockholders' equity increasing to 21.4 billion in 2025. The debt-to-equity ratio rose to 1.20 in 2025, indicating increased leverage which could pose a risk if not managed carefully. However, the equity ratio remains healthy at 37.3%, suggesting a stable financial foundation. Return on equity improved to 18% in 2025, signifying effective utilization of shareholder funds. While leverage has increased, the company maintains a strong equity position.
Cash Flow
72
Positive
The cash flow analysis reveals that operating cash flow has been steadily increasing, reaching 5.8 billion in 2025, highlighting robust operational performance. However, free cash flow has been negative, mainly due to high capital expenditures which could limit liquidity in the short term. The operating cash flow to net income ratio of 1.51 in 2025 suggests strong earnings quality. Despite the negative free cash flow, the company shows solid cash generation from operations.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue32.18B30.35B24.98B21.98B16.51B13.30B
Gross Profit22.12B9.10B14.82B6.99B10.34B4.19B
EBITDA8.24B7.83B6.53B6.51B5.42B3.78B
Net Income3.77B3.85B3.10B3.36B3.33B2.01B
Balance Sheet
Total Assets0.0057.36B38.52B29.41B19.07B14.36B
Cash, Cash Equivalents and Short-Term Investments1.02B1.02B1.32B1.34B1.90B2.84B
Total Debt0.0025.57B13.55B6.78B2.57B3.16B
Total Liabilities-24.19B33.17B17.59B10.03B4.97B5.60B
Stockholders Equity24.19B21.38B18.28B16.70B13.87B8.64B
Cash Flow
Free Cash Flow0.00-4.27B-1.26B-1.42B1.54B2.62B
Operating Cash Flow0.005.82B5.21B4.32B3.24B3.56B
Investing Cash Flow0.00-11.16B-7.53B-5.47B-4.12B-3.54B
Financing Cash Flow0.005.43B2.17B196.42M609.99M98.19M

Krishna Institute of Medical Sciences Limited Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price734.30
Price Trends
50DMA
731.43
Negative
100DMA
717.30
Positive
200DMA
665.93
Positive
Market Momentum
MACD
-2.00
Negative
RSI
48.53
Neutral
STOCH
51.61
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KIMS, the sentiment is Neutral. The current price of 734.3 is above the 20-day moving average (MA) of 712.25, above the 50-day MA of 731.43, and above the 200-day MA of 665.93, indicating a neutral trend. The MACD of -2.00 indicates Negative momentum. The RSI at 48.53 is Neutral, neither overbought nor oversold. The STOCH value of 51.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:KIMS.

Krishna Institute of Medical Sciences Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
₹372.21B68.980.04%15.42%10.66%
₹362.74B45.970.25%12.09%-2.79%
₹103.33B275.5116.85%-29.57%
₹288.08B76.5224.71%19.17%
₹824.98B94.330.09%14.04%32.99%
₹364.14B110.810.71%-53.19%-94.01%
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:KIMS
Krishna Institute of Medical Sciences Limited
734.30
189.80
34.86%
IN:ASTERDM
Aster DM Healthcare Ltd.
699.35
259.54
59.01%
IN:FORTIS
Fortis Healthcare Ltd.
1,055.40
430.04
68.77%
IN:HCG
HealthCare Global Enterprises Ltd.
777.55
328.20
73.04%
IN:MEDANTA
Global Health Limited
1,375.40
270.20
24.45%
IN:NH
Narayana Hrudayalaya Ltd.
1,799.50
530.14
41.76%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 14, 2025